NewLink Genetics to Present at the 36th Annual J.P. Morgan Healthcare Conference

By , in PR PR California on .

AMES, Iowa, Dec. 21, 2017 — NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will present at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 11:00am PT / 2:00pm ET in San Francisco, CA. 
A live webcast of the conference presentation will be on the Company's website at in the “Investors & Media” section under “Events & Presentations.”  About NewLink Genetics CorporationNewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer.  NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer.  Indoximod is being evaluated in combination with treatment regimens including anti-PD-1/PD-L1 agents, cancer vaccines, and chemotherapy across multiple indications such as melanoma, pancreatic cancer and other malignancies.  For more information, visit, and follow us on Twitter @NLNKGenetics.###Investor Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
(515) 598-2555
[email protected]
Media Contact:Vivian Ni
Public & Media Relations
617-374-8800, ext. 109
[email protected]

The following two tabs change content below.
Sarah Thompson

Sarah Thompson

Sarah is a financial reporter, focusing on technology, national security, and policing. Before joining Daily Telescope she worked as a staff writer at Fast Company and spent two years as a foreign correspondent in Turkey. Her work has been published in Al Jazeera America, The Nation, Vice News, Motherboard, and many other outlets.
%d bloggers like this: